Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. TRVN, NAVB, GNCA, PXMD, and ARDS

Should you buy Comera Life Sciences stock or one of its competitors? MarketBeat compares Comera Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Comera Life Sciences include Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.

How does Comera Life Sciences compare to Trevena?

Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Trevena$443K0.02-$40.29M-$47.04N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Trevena Neutral

Comera Life Sciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Trevena N/A N/A -119.55%

13.6% of Trevena shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Comera Life Sciences Neutral

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Comera Life Sciences (NASDAQ:CMRA) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Genocea Biosciences Neutral

0.6% of Genocea Biosciences shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

Comera Life Sciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Comera Life Sciences has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

Comera Life Sciences beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

4.9% of PaxMedica shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Aridis Pharmaceuticals Neutral

Comera Life Sciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, suggesting that its share price is 4,659% more volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.31N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Summary

Aridis Pharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$975.85M$6.87B$12.26B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio0.001.5327.1423.64
Price / SalesN/A104.46517.0889.45
Price / CashN/A20.0650.5459.64
Price / BookN/A8.4710.286.07
Net Income-$18M-$2.70M$3.60B$331.99M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
TRVN
Trevena
N/A$0.01
+640.0%		N/A-98.8%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
-28.6%		N/A+400.0%$6KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely | Sponsoredtc pixel
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel